AI-generated summary
This systematic review of 43 cell, animal, and human studies summarizes photobiomodulation and visual stimulation for cognitive decline and Alzheimer's disease pathology. The authors report that preclinical work suggests attenuation of amyloid and tau pathology, and that the few human studies support possible cognitive benefits. They state that clinical investigation is urgently required and that translational evidence remains limited.
- Studies included
- 43
- Who or what was studied
- Cell, animal, and human studies of cognitive decline and Alzheimer's disease pathology, including older subjects and AD patients
- Wavelengths
- 640, 810, 870 nm
- Limits stated in the abstract
- The abstract states that translational evidence is lacking, human studies are few, and reported parameters and outcomes vary with conflicting results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on alz-journals.onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810-870 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Cognitive decline, Systematic review. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.